Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech And US DoJ: A Snapshot Of 2016 Pay-Outs And Pleas

Executive Summary

The US Department of Justice has announced resolution of 14 device-related investigations in 2016, including settlements, guilty pleas and a few executive convictions. The largest settlement this year, with Olympus Corp., accounted for almost three-quarters of the $825.5m total value of medtech fines in 2016.

You may also be interested in...



Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds

US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.

Olympus Pays Record Anti-Kickback Penalty For Device Case

Olympus Corp. is making a record payment and implementing stricter internal compliance controls and monitoring to avoid prosecution on kickback allegations.

51 More Hospitals Join Federal ICD Settlement

The Department of Justice says the additional 51 hospitals that settled with the government on charges of billing for ICD implants outside of Medicare coverage guidelines represent the "final stage" of a long-running investigation. DoJ previously identified another 457 hospitals that have settled. Hospitals payments tied to the investigation total $273 million.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel